Brainomix Collaborated with Bridge Biotherapeutics for BBT-877 to Treat Idiopathic Pulmonary Fibrosis Using AI-Powered e-ILD Software
Shots:
- The collaboration will use Brainomix’s e-ILD technology, an AI-based program & will focus on quantitative analysis of imaging data in the P-II study to evaluate the safety, tolerability, and efficacy of BBT-877 (novel autotaxin inhibitor) for the treatment of IPF
- The collaboration enables Bridge to produce supplemental efficacy data from clinical studies on IPF patients, based on a combination of imaging technology & expertise
- Automated AI-driven quantitative imaging is designed to enhance trial design, increase a favorable treatment response & accelerate the translation of new treatments into clinical practice
Ref: PRNewswire | Image: Brainomix
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
